aclerastide
Peptideexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Oct 1, 2008 (NCT00796744)
Timeline
Indications
Mechanism of action
- AngiotensinogenSupplementation
AGT supplementation
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297940 ↗
Also known as
- aclerastide
- dsc127
- dsc127
- norleu3-a(1-7)
- norleu3-a(1-7)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03615196 | Phase 1 | Jul 25, 2018 | Department of Defense, US Biotest, WCCT Global |
| NCT01840085 | Phase 3 | Jun 1, 2013 | Derma Sciences, Inc., Integrium |
| NCT01849965 | Phase 3 | Apr 1, 2013 | Derma Sciences, Inc., Integrium |
| NCT01830348 | Phase 3 | Feb 1, 2013 | Derma Sciences, Inc., Integrium |
| NCT00796744 | Phase 2 | Oct 1, 2008 | Derma Sciences, Inc., National Institutes of Health (NIH), US Biotest |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Derma Sciences, Inc. | For profit | 4 | 3 | 2 | 2008 |
| Integrium | For profit | 3 | 0 | 1 | 2013 |
| US Biotest | For profit | 2 | 2 | 2 | 2008 |
| Department of Defense | Government | 1 | 0 | 1 | 2018 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2008 |
| WCCT Global | For profit | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1